Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04214418
Title Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies (MEKiAUTO)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Columbia University

Advanced Solid Tumor

colorectal adenocarcinoma


pancreatic adenocarcinoma


Atezolizumab + Cobimetinib + Hydroxychloroquine

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.